Search ↗

Comparison

GHRP-2 vs Sermorelin

GHRP-2 is gHRPs & ghrelin mimetics; Sermorelin is GHRH analogs. They are compared here because they are frequently considered against each other, not because they act alike.

On published evidence alone, Sermorelin is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

GHRP-2 Sermorelin
Class GHRPs & ghrelin mimetics GHRH analogs
Evidence Clinical trials Regulator approved
Human trials ~12 ~20
Half-life ~30 minutes ~10-20 minutes
Reported range 100-300 mcg 200-500 mcg
Frequency 2-3x daily Once daily at bedtime
Routes Subcutaneous, Intramuscular, Intranasal Subcutaneous
FDA approved No Yes
Research use only Yes No
Banned in sport Yes Yes
Studied for GH secretory testing, Growth hormone elevation, Appetite stimulation Growth hormone deficiency diagnosis and paediatric treatment, Age-related GH decline, Sleep quality, Body composition
Reported side effects Increased appetite, Elevated cortisol and prolactin, Water retention, Tiredness Injection-site erythema, Flushing, Headache, Transient dizziness

GHRP-2

GHRP-2 is a synthetic hexapeptide agonist at the growth hormone secretagogue receptor. It produces a larger GH pulse than ipamorelin at comparable doses, but with measurable increases in cortisol and prolactin, which is the trade-off that defines its position in the class. It is approved in Japan under the name pralmorelin as a diagnostic test of pituitary GH reserve.

Sermorelin

Sermorelin is a truncated analog of growth-hormone-releasing hormone comprising residues 1-29, the minimum sequence required for receptor activation. It binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of endogenous growth hormone. Because it acts upstream on the pituitary rather than replacing growth hormone directly, release remains subject to negative feedback from somatostatin and IGF-1, which is the usual argument for a lower risk of supraphysiologic exposure than exogenous hGH.

GHRP-2 vs Sermorelin: common questions

What is the difference between GHRP-2 and Sermorelin?

GHRP-2 is gHRPs & ghrelin mimetics and Sermorelin is GHRH analogs, so they act on different pathways. GHRP-2: A potent ghrelin-receptor agonist approved in Japan as a diagnostic agent, with a stronger GH pulse than ipamorelin and more hormonal spillover. Sermorelin: The first 29 amino acids of endogenous growth-hormone-releasing hormone, and the shortest fragment that retains full biological activity.

Which has stronger evidence, GHRP-2 or Sermorelin?

Sermorelin has the stronger evidence base (regulator approved, about 20 human studies) compared with GHRP-2 (clinical trials).

Are GHRP-2 and Sermorelin FDA approved?

Only Sermorelin is FDA approved (Diagnostic assessment of pituitary GH secretory capacity (Geref); Treatment of idiopathic growth hormone deficiency in children with growth failure (Geref, approved 1997; discontinued by the manufacturer in 2008, not for safety reasons)). GHRP-2 is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 6918245) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 158861-67-7 ↗ · chemical identity
  5. PubChem compound record (CID 16132413) ↗ · structure, identifiers, synonyms
  6. DailyMed: FDA-approved labeling for Sermorelin ↗ · indications, dosing, warnings as approved
  7. FDA Drugs@FDA database ↗ · approval history
  8. CAS Registry Number 86168-78-7 ↗ · chemical identity

Published literature

  1. Ghigo E, Arvat E, Muccioli G, et al.. Growth hormone-releasing peptides.Eur J Endocrinol 1997.PubMed 9186261 · doi:10.1530/eje.0.1360445
  2. Fukuda I, Hizuka N, Muraoka T, et al.. Adult growth hormone deficiency: current concepts.Neurol Med Chir (Tokyo) 2014.PubMed 25070016 · doi:10.2176/nmc.ra.2014-0088
  3. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.Drugs R D 2004.PubMed 15230633 · doi:10.2165/00126839-200405040-00011
  4. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs.Front Neuroendocrinol 1998.PubMed 9465289 · doi:10.1006/frne.1997.0158
  5. Vodnik M, Štrukelj B, Lunder M. Ghrelin Receptor Ligands Reaching Clinical Trials: From Peptides to Peptidomimetics; from Agonists to Antagonists.Horm Metab Res 2016.PubMed 26551992 · doi:10.1055/s-0035-1564149
  6. Muccioli G, Broglio F, Valetto MR, et al.. Growth hormone-releasing peptides and the cardiovascular system.Ann Endocrinol (Paris) 2000.PubMed 10790589
  7. Celichowska M, Miedziaszczyk M, Lacka K. Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy.J Pain Palliat Care Pharmacother 2022.PubMed 35758863 · doi:10.1080/15360288.2022.2063469
  8. Argente J, García-Segura LM, Pozo J, et al.. Growth hormone-releasing peptides: clinical and basic aspects.Horm Res 1996.PubMed 8950613 · doi:10.1159/000185015
  9. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  11. Memdouh S, Gavrilović I, Ng K, et al.. Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug Test Anal 2021.PubMed 34665524 · doi:10.1002/dta.3183
  12. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?.Clin Interv Aging 2006.PubMed 18046908 · doi:10.2147/ciia.2006.1.4.307
  13. Ramirez G, Herrera R, Pineda D, et al.. The effects of high altitude on hypothalamic-pituitary secretory dynamics in men.Clin Endocrinol (Oxf) 1995.PubMed 7641401 · doi:10.1111/j.1365-2265.1995.tb01887.x
  14. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
  15. Popovic V, Pekic S, Golubicic I, et al.. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.J Clin Endocrinol Metab 2002.PubMed 11994347 · doi:10.1210/jcem.87.5.8485
  16. Saenger P, Pescovitz OH, Bercu BB, et al.. Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone.Endocrine 2001.PubMed 11572326 · doi:10.1385/ENDO:15:1:051

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.